GEF-Inhibitors: New small molecules for the treatment of autoimmune and malignant diseases
Scientists at the University of Bonn have identified new small molecules which can be used for the treatment of diseases characterized by alterations of proteins which are affected by Guanine nucleotide Exchange Factors (GEFs). Proteins targeted by GEFs are involved in integrin signalling, vesicle transport, or MAPK-signalling. These processes play an important role in the modulation of the immune response. Therefore, abnormal activation of the target proteins of GEFs can cause autoimmune and tumor diseases in humans.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Duke-NUS and NHCS scientists first in the world to regenerate diseased kidney
Blocking an immune-regulating protein reverses the damage caused by acute and chronic kidney disease, a preclinical study suggests. In a world first, scientists at Duke-NUS Medical School, the National Heart…
Unconventional superconductivity found in kagome metal
Physicists using advanced muon spin spectroscopy at Paul Scherrer Institute PSI make the missing link between their recent breakthrough in a kagome metal and unconventional superconductivity. The team uncovered an…
Discovery of new ice may change understanding of water
Researchers at UCL (University College London) have discovered a new type of ice that more closely resembles liquid water than any other known ices and that may rewrite our understanding…
